Since accumulating evidence indicated that BTKi is an emerging therapeutic strategy against inflammatory diseases [24, 25], we also discussed the application of BTKi in the management of inflammatory disorders, such as SLE, rheumatoid arthritis (RA), MS, and idiopathic thrombocytopenic purpura (ITP). This evidence concerns the gene IBTK and rheumatoid arthritis.